

pSELECT-zeo-Fcy::fur

A plasmid encoding a CpG-free cytotoxic fusion gene

Catalog code: psetz-fcyfur

For research use only

Version 20K30-MM

PRODUCT INFORMATION

Content:

- 20 µg of pSELECT-zeo-Fcy::fur plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

Product is shipped at room temperature. Lyophilized DNA should be resuspended upon receipt and stored at -20°C. Lyophilized DNA is stable 3 months at -20°C. Resuspended DNA is stable more than one year at -20°C.
Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pSelect-zeo plasmids contain genes that have been chemically synthesized. The DNA sequence of these genes was modified by optimizing the codon usage, reducing or eliminating the CpG motifs and avoiding secondary DNA structures without changing the amino acid sequence of the wild type proteins.

pSELECT-zeo-Fcy::fur encodes a synthetic CpG-free suicide gene. Suicide genes code for enzymes that convert non-toxic compounds (prodrugs) into toxic products.

pSELECT-zeo-Fcy::fur can also be used to subclone this synthetic suicide gene into another vector. To facilitate subcloning, the Fcy::fur gene is flanked by two unique restriction sites: Nco I at the 5' end that encompasses the Start codon, and Nhe I at the 3' end.

PLASMID FEATURES

First expression cassette

• **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1alpha (EF-1 α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1 α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1 α core promoter to enhance stability of RNA.

• **Fcy::fur:** Synthetic CpG-free *S. cerevisiae* cytosine deaminase-uracil phosphoribosyl transferase fusion gene. InvivoGen has fused the gene encoding uracil phosphoribosyl transferase (UPRT) to the cytosine deaminase (CD) gene. CD converts cytosine and its analogue, 5-fluorocytosine (5-FC), to uracil and 5-fluorouracil (5-FU) respectively. 5-FU is a toxic compound commonly used as anticancer drug. UPRT converts 5-FU to 5-FUMP, an irreversible inhibitor of thymidylate synthase. CD::UPRT fusions are 100 times more efficient than the CD genes alone and provide greater bystander effect.

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.

• **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

Second expression cassette

• **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.

• **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

• **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptallosteichus hindustanus*. The *Sh ble* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

• **BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

1. Kim, D.W. *et al.* (1990). Gene 2: 217-223.
2. Takebe, Y. *et al.* (1988). Mol. Cell Biol. 1: 466-472.
3. Carswell, S. & Alwine, J.C. (1989). Mol. Cell Biol. 10: 4248-4258.
4. Yu J & Russell JE. (2001). Mol Cell Biol, 21(17):5879-88.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



Eagl (1)
NotI (-1)
 1 **GGCGCCG**AATAAAATCTTATTTCATTACATCTGTGTTGGTTTGTGAATCGTAACATAGCCTCTCCATCAAACAAAACGAAACA
PvuI (172)
Sgfl (171)
 101 AAACAAACTAGCAAAATAGGCTGCCAGTGCAGTGCCAGAACATTCTATCGAAGGATCTCGCATCGTCCGGTCCGTCACTGGGAAAGTGT
 201 GAGCGCACATGCCACAGTCCCAGAAGTTGGGGAGGGTGGCAATTGAACGGGTGCTAGAGAAGGTGGCGGGTAAACTGGGAAAGTGT
 300 GTCGTGACTGGCTCCGCTTTCCGAGGGTGGGGAGAACCGTATAAGTCAGTAGTCGCCGTGACCGTCTTTGCAACGGTTGCC

HindIII (410)
PvuII (404)
 400 GAACACAGCTGAAGCTTCGAGGGGCTCGATCTCCTTCACGGCCGCCACCTGAGGCCATCCACGCCGGTGAAGCTGCT
 500 TCCGCCGTGGTGCCTCTGAACCTGCTCCGCTAGGTAAAGCTCAGGTGAGACCGGGCTTGTCCGGCCTGGAGCCACCT
 600 AGACTCAGCCGCTCCACGCTTGCTGACCTGCTGCACTCTACGCTTGTGCTTGTGCGCCGTTACAGATCCAAGCTGTGAC

Ncol (725)
KasI (700)
 700 CGGGCCTACCTGAGATCACgggtcacCATGGTCACAGGAGGCATGGCTCAAAGTGGACCAGAAGGGCATGGACATTGCCTATGAGGAGGCTGCTG
 800 GGCTACAAGGAGGGGGGGTCCCAATTGGTGGCTGCCTCATCAAACAAGGATGGCAGTGTCTGGCAGGGCCACACATGAGGTTCCAGAAGGGCA
 25 G Y K E G G V P I G G C L I N N K D G S V L G R G H N M R F Q K G
BsrGI (977)
 900 GTGCCACCTGCATGGGGAGTCAGCACCTGGAGAACTGTGGCAGGCTGGAGGAATGTCACAGGACACCACTGTGACACCCCTCAGCCCTG
 58 S A T L H G E I S T L E N C G R L E G K V Y K D T T L Y T T L S P C

BstXI (1037)
BspLU11I (1001)
 1000 TGACATGTCACAGGGGCATCATGTATGGCATTCCAGGTGTGGTGGAGAGAATGTCACAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTC
 91 D M C T G A I I M Y G I P R C V V G E N V N F K S K G E K Y L Q T
XcmI (1149)
 1100 AGGGCCATGAGGGGGTGTGGTGGATGATGAGAGGGTCAAGAAGATTATGAAAGCAGTCATTGATGAGAGACCCAGGACTGGTTGAGGACATTGGG
 125 R G H E V V V V D D E R C K K I M K Q F I D E R P Q D W F E D I G
StuI (1199)
 1200 AGGCCTCTGAGCCCTCAAGAATGTCACCTCTCCCCAGACCAACACTCTGGACTCACCATCATCAGAACAGAACACCCAGGCCAGA
 158 E A S E P F K N V Y L L P Q T N Q L L G L Y T I I R N K N T T R P D
 1300 CTTCATCTTACAGTGCAGGATCATCAGGCTCTGGTGGAGGGCCTAACACCCTCCGTGCAAGAGCAGATTGTGGAGACTGACACCAATGAG
 191 F I F Y S D R I I R L L V E E G L N H L P V Q K Q I V E T D T N E
Bsu36I (1476)
 1400 AACTTGAGGGAGTGTCTTCATGGCAAGATTGTGGGTGTCATTGAGGGCTGGGAGAGCATGGGAGGGACTGTGAGGAGTCAGGAGT
 225 N F E G V S F M G K I C G V S I V R A G E S M E Q G L R D C C R S

BsaBI (1512)
 1500 TGAGGATTGGCAAGATCTGATCCAGGGATGAGGAGACTGCCCTGCCAACGCTGTTATGAGAAGCTCCCTGAAGACATCTGAGAGGTATGTCTT
 258 V R I G K I L I Q R D E E T A L P K L F Y E K L P E D I S E R Y V F
 1600 CCTCTGGACCCCATGCTGGCAACTGGAGGCTCTGCAATCATGGCAACTGAGGTGCTCATCAGAGGGAGTCAGCCTGAGAGGATCTACTTCTCAAC
 291 L L D P M L A T G G S A I M A T E V L I K R G V K P E R I Y F L N
 1700 CTCATCTGCTCAAAGGGGGCATTGAGAAGTACCATGCTGCCCTCTGAAGTGAAGGATTGTCACTGGGCTCTGGCAGGGCCTGGATGAGAACAGT
 325 L I C S K E G I E K Y H A A F P E V R I V T G A L D R G L D E N K

NheI (1855)
 1800 ACCTGGCCCTGGCTGGAGACTTGGGACAGATACTACTGTGTCAAACCTGAGCTAGTGGCCAGACATGATAAGATAACATTGATGAGTTGGACA
 358 Y L V P G L G D F G D R Y Y C V •

HpaI (1993)
 1900 ACCACAACTAGAATGCACTGAAAAAAATGCTTATTGTGAATTGTGATGCTATTGTTATTGTAACATTATAAGCTGAATAAACAGTTAAC

EcoRI (2089)
 2000 AACACAATTGCATTCTTATGTTCAAGGTTAGGGGAGGGTGTGGAGGTTTAAAGCAAGTAAACCTCTACAAATGTTGATGAAATTCTAA
 2100 ATACAGCATAGCAAACCTTAACTCCAAATCAAGCTCTACTTGAATCCTTCTGAGGTGATAAGGCACTAGGCATCGGGCTTGCCATGTC
 2200 CATTAGCTGTTGCAGCTCACCTCTTCAAGATATAGTGTATTCTTCAAGGTTGAACTAGCTCTCATTTTATGTTAAATGC

SspI (2328) SwaI (2342)
 2300 ACTGACCTCCACATTCTTTAGAAAATTCAGAAATAATTAAATCATCATTGCAATGAAAATAATGTTTATTAGGCAGAACCCAGATG
 2400 CTCAGGCCCTCATATAATCCCCAGTTAGTGGACTTAGGAACAAAGAACCTTAATAGAAATTGGACAGCAAGAACGAGCTCTAGCTT

 127 • •
DraIII (2521) Eagl (2541)
 2500 ATCCCTAGTCTGCTCTGCCACAAAGTCAGCGAGTGGCCGGGGTGCAGGGCAACTCCGCCACGGCTGCTGCCATCGGT
 126 G • D Q E E A V F H V C N G A P D R L A F E R G W P Q E G I E T M
 2600 GGCGGGCCGGAGGGTCCCGGAAGTCTGAGACAGACCTCGGACACTCGGCTAGCCTGTCAGGGCAGGCCACACCCAGGCCAGGGTTG
 93 A P G S A D R F N T S V V E S W E A Y L E D L G R V W V W A L T N

SgrAI (2757) XmaI (2784)
 2700 TCCGGCACACCTGGCTGGACCGCGCTGATGAACAGGGTACGTCGCTCCGGACACCGGGCAAGTCCGGCACGAAGTCCGGAGAACCCGA
 59 D P V V Q D Q V A S I F L T V D D R V V G A F D D E V F D R S F G L
BsrBI (2820)
 2800 GCCGGTGGTCAGAACCTGACCGCTCCGGCGAGCTGGAGACCCGGAAACGGCACTGGTCAACTGGCCATGAGGGCTCTTATAGTGA
 26 R D T W F E V A G A V D R A T L V P V A S T L K A M
Asel (2932)
 2900 CGTATTATACTATGCCATATACTATGCCATGATGTTAAATTGTCACACAGCGTGGATGGCGTCTCCAGCTTATGACGGTCACTAACAGAGCTGCT

SpeI (3087)

3000 TATATAGACCTCCACCGTACACGCCATTCGCTCAATGGGGCGGAGTTACGACATTGGAAAGTCCGTTGATTACTAGTCAAAC

3100 AAACTCCCATTGACGTCAATGGGGTGGAGACTTGAAATCCCGTGAGTCACCGCTATCCACGCCATTGATGACTGCCAAAACGCATCATCATGG

SnaBI (3215)

3200 TAATAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCATAAGGTATGACTGGCATAATGCCAGGCAGGCCATTACCGTATTGAC

NdeI (3320)

3300 GTCAATAGGGGGCGTACTTGGCATATGATAACACTTGATGACTGCCAAGTGGCAGTTACCGTAATAACTCCACCCATTGACGTCAATGGAAAGTCCCT

3400 ATTGGCGTTACTATGGGAACATACGTATTGACGTCAATGGCGGGGTCGTTGGCGGTAGCCAGGCAGGCCATTACCGTAAGTTATGTAACGC

PacI (3506)**PstI (3499) BspLU11I (3516)**

3500 CTGCAGTTAATTAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCAGTTGCTGGCTTTCCATAGGCTCCGCCCTC



3600 GACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACAGGACTATAAGATACCAGCGTTCCCCCTGAAAGCTCCCTGCGCT

3700 CTCCTGTTCCGACCTGCGCTTACCGGATACTCTGCGCTTCTCCCTCGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTT

3800 GGTGTAGGTCGTTCGCTCCAAGCTGGCTGTGTCAGAACCCCCGTTAGCCGACCGCTGCGCTTATCGGTAACATCTGTTGAGTCCAACCCG

3900 GTAAGACACGACTTATGCCACTGGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGAGGCGGTGCTACAGAGTTGAAGTGGCTA

4000 ACTACGGCTACACTAGAAGAACAGTATTGGTATCTCGCTCTGTAAGGCCAGTTACCTCGGAAAAAGAGTTGGTAGCTTGTACGGCAACAAAC

4100 CACCGCTGGTAGCGGTGTTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGATCTAAGAAGATCCTTGATCTTGTACGGGTCTGAC

PacI (4246)SwI (4255)

4200 GCTCAGTGGAACGAAACTCACGTTAAGGGATTTGGTACGGCTAGTTAATTACATTAAATCA